$LLY

Lilly TuneLab, Twist Bioscience Partner on Antibody Drug Discovery

Eli Lilly's AI/ML drug discovery platform, Lilly TuneLab, partners with Twist Bioscience to provide antibody characterization data. Twist's services will support TuneLab's antibody developability prediction model, AbLab, aiming to accelerate drug discovery. Twist's CEO highlights the importance of high-quality data for AI models. The partnership leverages Twist's scale and TuneLab's AI capabilities, offering preferred protocols and pricing for users.

Original reporting
Published Sep 16, 2026, 4:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 6:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Lilly TuneLab, Twist Bioscience Partner on Antibody Drug Discovery — source image
Decision brief

The 30-second read

$LLYBullishLow
01

Why it matters

The partnership could enhance both companies' positions in AI‑enabled biotech, though immediate financial impact is unclear.

02

Market read

Strategic AI‑biotech collaboration with potential long‑term revenue upside for both firms.

03

What to watch

Execution risk and dependence on data quality could affect the partnership's success.

Relevance 5/10Novelty 6/10Timing: announcement today

Background

Eli Lilly's AI platform TuneLab aims to accelerate antibody discovery by leveraging high‑quality wet‑lab data.

Company-level read

Ticker impact

$LLYBullishMedium confidence
Context

Eli Lilly's TuneLab AI platform partners with Twist Bioscience to provide antibody characterization data.

Expected impact

Modest upside for LLY as partnership may drive future collaborations.

Evidence & confidence

First announcement of the partnership, no financial terms disclosed, but strategic fit is strong.

$TWSTBullishMedium confidence
Context

Twist Bioscience signs agreement to supply antibody data for Lilly's TuneLab platform.

Expected impact

Slight upside potential for TWST pending execution of the deal.

Evidence & confidence

New partnership announced, no monetary details, but adds a high‑profile client.

Market effects

Highlights growing AI integration in biotech, may spur similar collaborations.

U.S. biotech and AI sectors see modest positive sentiment.

Shows cross‑border potential for AI‑driven drug discovery platforms.

Counterpoint

Without disclosed financial terms, the partnership may have limited near‑term revenue impact.

Key entities

  • Eli Lilly and Company

    Pharmaceutical giant providing the TuneLab AI platform.

  • Twist Bioscience

    Biotech firm supplying antibody characterization services.

Related articles

$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.

$LLYMedAI 8/10

QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases

QurCan Therapeutics and Eli Lilly have entered a research and collaboration agreement to develop nucleic acid therapies for central and peripheral nervous system diseases. Lilly will invest strategically in QurCan, which could receive up to $237 million per program in milestones and royalties. QurCan will optimize therapeutics using its TERP platform, while Lilly will handle further research, clinical development, and commercialization.